LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) has earned a consensus rating of “Hold” from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $108.25.
A number of research analysts have issued reports on the stock. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a research report on Thursday, November 5th. Seaport Research Partners set a $110.00 price target on LeMaitre Vascular in a research note on Thursday, November 5th. Weiss Ratings downgraded LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 23rd. Finally, Citizens Jmp initiated coverage on LeMaitre Vascular in a research report on Thursday, November 5th. They set a “market outperform” rating and a $110.00 price target on the stock.
Check Out Our Latest Research Report on LeMaitre Vascular
LeMaitre Vascular Stock Performance
NASDAQ LMAT opened at $78.29 on Monday. The firm has a 50-day moving average of $81.31 and a 200-day moving average of $93.95. The company has a debt-to-equity ratio of 0.39, a quick ratio of 12.54 and a current ratio of 14.60. The stock has a market cap of $1.79 billion, a PE ratio of 28.47, a P/E/G ratio of 2.31 and a beta of 0.51. LeMaitre Vascular has a 52-week low of $77.46 and a 52-week high of $118.01.
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.04). LeMaitre Vascular had a net margin of 23.51% and a return on equity of 15.33%. The firm had revenue of $67.97 million during the quarter, compared to analyst estimates of $67.39 million. During the same period in the prior year, the company earned $0.75 earnings per share. The business’s quarterly revenue was up 11.3% compared to the same quarter last year. On average, sell-side analysts anticipate that LeMaitre Vascular will post 2.83 EPS for the current year.
LeMaitre Vascular Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Thursday, November 19th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date is Thursday, November 19th. LeMaitre Vascular’s dividend payout ratio is presently 36.36%.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new position in LeMaitre Vascular in the 2nd quarter valued at about $314,075,000. First Trust Advisors LP grew its position in shares of LeMaitre Vascular by 6.2% in the 1st quarter. First Trust Advisors LP now owns 998,071 shares of the medical instruments supplier’s stock valued at $108,959,000 after buying an additional 57,931 shares during the last quarter. Copeland Capital Management LLC increased its position in shares of LeMaitre Vascular by 10.1% during the third quarter. Copeland Capital Management LLC now owns 924,081 shares of the medical instruments supplier’s stock worth $76,320,000 after buying an additional 84,618 shares during the period. Advisors Asset Management Inc. acquired a new stake in LeMaitre Vascular in the third quarter worth $49,581,000. Finally, Boston Trust Walden Corp bought a new position in shares of LeMaitre Vascular in the third quarter valued at $28,546,000. Institutional investors own 84.64% of the company’s stock.
LeMaitre Vascular Company Profile
LeMaitre Vascular develops, manufactures and markets medical devices used primarily in the treatment of vascular disease. Its products support procedures performed by vascular surgeons and include vascular grafts, embolectomy catheters, carotid shunts, valvulotomes and other instruments used in vascular surgery. Founded in 1983 by vascular surgeon George LeMaitre, the company is headquartered in Burlington, Massachusetts. Its products are sold to hospitals and medical professionals around the world through a combination of direct sales and distributors.
Further Reading
- Five stocks we like better than LeMaitre Vascular
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
